[Developing lines in psychoendocrinology].
D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000818:Animals; D003348:Cortisone / Q000009:adverse effects; D004565:Electroconvulsive Therapy; D004700:Endocrine System Diseases / Q000150:complications*; D006728:Hormones / Q000502:physiology*; D006801:Humans; D007858:Learning / Q000187:drug effects; D009075:MSH Release-Inhibiting Hormone / Q000378:metabolism; D008568:Memory / Q000187:drug effects; D001523:Mental Disorders / Q000209:etiology* / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000378:metabolism; D010455:Peptides / Q000378:metabolism; D011605:Psychoses, Substance-Induced / Q000209:etiology; D011619:Psychotropic Drugs / Q000494:pharmacology; D012559:Schizophrenia / Q000378:metabolism; D013002:Somatomedins / Q000378:metabolism; D013004:Somatostatin / Q000378:metabolism; D013256:Steroids / Q000378:metabolism; D013373:Substance P / Q000378:metabolism; D013972:Thyrotropin / Q000378:metabolism; D014667:Vasopressins / Q000494:pharmacology
D006728:Hormones; D009419:Nerve Tissue Proteins; D010455:Peptides; D011619:Psychotropic Drugs; D013002:Somatomedins; D013256:Steroids; D014667:Vasopressins; D013373:Substance P; D013004:Somatostatin; D000324:Adrenocorticotropic Hormone; D013972:Thyrotropin; D009075:MSH Release-Inhibiting Hormone; D003348:Cortisone
Utvecklingslinjer inom psykoendokrinologin